Cargando…

The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hijacks multiple human proteins during infection and viral replication. To examine whether any viral proteins employ human E3 ubiquitin ligases, we evaluated the stability of SARS-CoV-2 proteins with inhibition of the ubiquitin proteasome...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Charles, Yoon, Hojong, Park, Paul M.C., Patten, J.J., Pellman, Jesse, Carreiro, Jeannie, Tsai, Jonathan M., Li, Yen-Der, Roy Burman, Shourya S., Donovan, Katherine A., Gasser, Jessica, Sperling, Adam S., Nowak, Radosław P., Fischer, Eric S., Davey, Robert A., Ebert, Benjamin L., Słabicki, Mikołaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082641/
https://www.ncbi.nlm.nih.gov/pubmed/37095859
http://dx.doi.org/10.1016/j.isci.2023.106601
Descripción
Sumario:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hijacks multiple human proteins during infection and viral replication. To examine whether any viral proteins employ human E3 ubiquitin ligases, we evaluated the stability of SARS-CoV-2 proteins with inhibition of the ubiquitin proteasome pathway. Using genetic screens to dissect the molecular machinery involved in the degradation of candidate viral proteins, we identified human E3 ligase RNF185 as a regulator of protein stability for the SARS-CoV-2 envelope protein. We found that RNF185 and the SARS-CoV-2 envelope co-localize to the endoplasmic reticulum (ER). Finally, we demonstrate that the depletion of RNF185 significantly increases SARS-CoV-2 viral titer in a cellular model. Modulation of this interaction could provide opportunities for novel antiviral therapies.